Vetter Managing Director to Retire Following Over Three Decades of Service

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has announced the retirement of its Managing Director, Thomas Otto, after more than 35 years with the company. Mr. Otto will officially step down from his position at the end of 2025.

Through his leadership and commitment, Mr. Otto has been instrumental in shaping the sustainable development and continued growth of the organization during his tenure.

During the transitional period, Mr. Otto will continue to serve in an advisory capacity, providing consultation on the planned development of a new production site in Germany.

The company has already prepared for the transition. Earlier in 2025, long-term experienced Vetter executives Henryk Badack, Titus Ottinger, and Carsten Press were appointed as Managing Directors to the Management Board. Their in-depth understanding of the company, its clientele, and the industry is expected to significantly contribute to Vetter’s sustainable future.

Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and a member of the owner family, expressed gratitude for Mr. Otto’s contributions: “His contribution to Vetter’s development and internationalization is outstanding and deserves the highest recognition. For more than three decades, he was a reliable designer, initiator and bridge builder. On behalf of the Vetter family and the advisory board, I would like to thank him for his extraordinary commitment and lasting impact on our success story.”

Source: https://www.contractpharma.com/breaking-news/vetter-managing-director-to-retire/

  • Related Posts

    Biotech Acquirer Xoma to Acquire Generation Bio

    Xoma Royalty, a company that has recently established a business strategy centered on acquiring distressed biotechnology firms, has secured its latest target. In a late Monday announcement, Xoma stated it…

    Sanofi Secures Deals for Novel Alzheimer’s Drug and Next-Generation Autoimmune Therapy

    On December 15, 2025, Sanofi announced two significant strategic collaborations aimed at strengthening its advanced therapeutic development pipelines. 1. Agreement with ADEL for Potential Alzheimer’s Drug (ADEL-Y01) Sanofi entered into…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    CARE PROVIDING APPROPRIATE FIRST AID WHILE AWAITING MEDICAL SUPPORT – PART 3: Proper CARE makes the difference between critical danger and recovery

    • By vivi
    • December 25, 2025
    • 1 views
    CARE PROVIDING APPROPRIATE FIRST AID WHILE AWAITING MEDICAL SUPPORT – PART 3: Proper CARE makes the difference between critical danger and recovery

    Stress Mastery: Ten Evidence-Based Strategies for Reclaiming Balance

    • By vivi
    • December 24, 2025
    • 1 views
    Stress Mastery: Ten Evidence-Based Strategies for Reclaiming Balance

    Anorexia Nervosa: Understanding and the Path to Wellness

    • By vivi
    • December 24, 2025
    • 1 views
    Anorexia Nervosa: Understanding and the Path to Wellness

    Psychological Recovery Roadmap: Strategies to Overcome Depression

    • By vivi
    • December 24, 2025
    • 1 views
    Psychological Recovery Roadmap: Strategies to Overcome Depression

    Mastering Leadership: Five Principles for Impactful Feedback

    • By vivi
    • December 24, 2025
    • 1 views
    Mastering Leadership: Five Principles for Impactful Feedback

    Elevating Team Excellence via the Playing Cards Method™ for Feedback

    • By vivi
    • December 24, 2025
    • 2 views
    Elevating Team Excellence via the Playing Cards Method™ for Feedback